BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Cernea S, Onișor D. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World J Gastroenterol 2023; 29(2): 286-309 [PMID: 36687124 DOI: 10.3748/wjg.v29.i2.286] [Reference Citation Analysis]
2 Gutiérrez-Cuevas J, Lucano-Landeros S, López-Cifuentes D, Santos A, Armendariz-Borunda J. Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. Cancers (Basel) 2022;15. [PMID: 36612019 DOI: 10.3390/cancers15010023] [Reference Citation Analysis]
3 Seko Y, Kawanaka M, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Okanoue T, Itoh Y, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia. J Gastroenterol Hepatol 2022;37:2313-20. [PMID: 36198983 DOI: 10.1111/jgh.16019] [Reference Citation Analysis]
4 Izquierdo AG, Carreira MC, Rodriguez-Carnero G, Perez-Lois R, Seoane LM, Casanueva FF, Crujeiras AB. Gender Dimorphism in Hepatic Carcinogenesis-Related Gene Expression Associated with Obesity as a Low-Grade Chronic Inflammatory Disease. Int J Mol Sci 2022;23. [PMID: 36499327 DOI: 10.3390/ijms232315002] [Reference Citation Analysis]
5 Machairas N, Papaconstantinou D, Dorovinis P, Tsilimigras DI, Keramida MD, Kykalos S, Schizas D, Pawlik TM. Meta-Analysis of Repeat Hepatectomy versus Radiofrequency Ablation for Recurrence of Hepatocellular Carcinoma. Cancers 2022;14:5398. [DOI: 10.3390/cancers14215398] [Reference Citation Analysis]
6 Younossi ZM, Paik JM, Al Shabeeb R, Golabi P, Younossi I, Henry L. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology 2022;76:1423-37. [PMID: 35363908 DOI: 10.1002/hep.32499] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 16.0] [Reference Citation Analysis]
7 Rusu I, Pirlog R, Chiroi P, Nutu A, Puia VR, Fetti AC, Rusu DR, Berindan-Neagoe I, Al Hajjar N. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC. Int J Mol Sci 2022;23:12370. [PMID: 36293225 DOI: 10.3390/ijms232012370] [Reference Citation Analysis]
8 Liu J, Liu T, Zhang C, He J, Zhou D, Wang Z, Wang R. EIF2S2 is a novel independent prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Front Genet 2022;13:992343. [DOI: 10.3389/fgene.2022.992343] [Reference Citation Analysis]
9 Cavalcante LN, Dezan MGF, Paz CLDSL, Lyra AC. RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Arq Gastroenterol 2022. [DOI: 10.1590/s0004-2803.202204000-93] [Reference Citation Analysis]
10 Filliol A, Schwabe RF. Liver cancer metabolism: a hexokinase from the stars. Nat Metab 2022;4:1225-6. [PMID: 36192600 DOI: 10.1038/s42255-022-00659-w] [Reference Citation Analysis]
11 Cazac G, Lăcătușu C, Mihai C, Grigorescu E, Onofriescu A, Mihai B. Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes. Biomedicines 2022;10:2375. [DOI: 10.3390/biomedicines10102375] [Reference Citation Analysis]
12 Risaliti M, Bartolini I, Campani C, Arena U, Xodo C, Adotti V, Rosi M, Taddei A, Muiesan P, Amedei A, Batignani G, Marra F. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis. World J Gastroenterol 2022; 28(29): 3981-3993 [DOI: 10.3748/wjg.v28.i29.3981] [Reference Citation Analysis]
13 Cazac GD, Lăcătușu CM, Mihai C, Grigorescu ED, Onofriescu A, Mihai BM. New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis. Life (Basel) 2022;12:1189. [PMID: 36013368 DOI: 10.3390/life12081189] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Craciun A, Cortez-pinto H. Alarming increase of NASH as cause of liver cancer. Cell Reports Medicine 2022;3:100723. [DOI: 10.1016/j.xcrm.2022.100723] [Reference Citation Analysis]
15 Toyoda H, Kariyama K, Hiraoka A. Editorial: non-viral hepatocellular carcinoma surveillance-an increasingly severe public health issue. Authors' reply. Aliment Pharmacol Ther 2022;56:750-1. [PMID: 35879905 DOI: 10.1111/apt.17139] [Reference Citation Analysis]
16 Caviglia GP, Nicolosi A, Abate ML, Carucci P, Rosso C, Rolle E, Armandi A, Aneli S, Olivero A, Risso A, Ribaldone DG, Fermer C, Saracco GM, Gaia S, Bugianesi E. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. Current Oncology 2022;29:5457-5465. [DOI: 10.3390/curroncol29080431] [Reference Citation Analysis]
17 Ueno M, Takeda H, Takai A, Seno H. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives. World J Gastroenterol 2022; 28(27): 3410-3421 [DOI: 10.3748/wjg.v28.i27.3410] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Han AL, Lee HK. Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease. Metabolites 2022;12:664. [DOI: 10.3390/metabo12070664] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Lange UG, Moulla Y, Schütz T, Blüher M, Peter V, Shang E, Dietrich A. Effectiveness and Tolerability of a Two-Week Hypocaloric Protein-Rich Diet Prior to Obesity Surgery with Two Different Diet Interventions: a Prospective Randomized Trial. OBES SURG. [DOI: 10.1007/s11695-022-06180-z] [Reference Citation Analysis]
20 Tulessin M, Sarker RSJ, Griger J, Leibing T, Geraud C, Weichert W, Steiger K, Mogler C. Vascular Remodeling Is a Crucial Event in the Early Phase of Hepatocarcinogenesis in Rodent Models for Liver Tumorigenesis. Cells 2022;11:2129. [DOI: 10.3390/cells11142129] [Reference Citation Analysis]
21 De Brandt E, Hillary T. Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management. PTT 2022;Volume 12:113-126. [DOI: 10.2147/ptt.s293107] [Reference Citation Analysis]
22 Pons M, Rivera-Esteban J, Manzano R, Bañares J, Bermúdez M, Vargas V, Salcedo-Allende MT, Castells L, Augustin S, Mínguez B, Pericàs JM. Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD. J Clin Med 2022;11:2466. [PMID: 35566592 DOI: 10.3390/jcm11092466] [Reference Citation Analysis]
23 Machairas N, Tsilimigras DI, Pawlik TM. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers 2022;14:2018. [DOI: 10.3390/cancers14082018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
24 Umemura A, Kataoka S, Okuda K, Seko Y, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Potential Therapeutic Targets and Promising Agents for Combating NAFLD. Biomedicines 2022;10:901. [DOI: 10.3390/biomedicines10040901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Trifan A, Rotaru A, Stafie R, Stratina E, Zenovia S, Nastasa R, Huiban L, Cuciureanu T, Muzîca C, Chiriac S, Gîrleanu I, Sîngeap A, Sfarti C, Cojocariu C, Stanciu C. Clinical and Laboratory Characteristics of Normal Weight and Obese Individuals with Non-Alcoholic Fatty Liver Disease. Diagnostics 2022;12:801. [DOI: 10.3390/diagnostics12040801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Repáraz D, Aparicio B, Llopiz D, Hervás-Stubbs S, Sarobe P. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens? Int J Mol Sci 2022;23:2022. [PMID: 35216137 DOI: 10.3390/ijms23042022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Feng Z, Xiang J, Liu H, Li J, Xu X, Sun G, Zheng R, Zhang S, Liu J, Yang S, Xu Q, Wen X, Yuan H, Sun H, Dai L. Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem . [DOI: 10.1021/acs.jmedchem.1c02002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Massart J, Begriche K, Hartman JH, Fromenty B. Role of Mitochondrial Cytochrome P450 2E1 in Healthy and Diseased Liver. Cells 2022;11:288. [DOI: 10.3390/cells11020288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
29 Hakami A, Elmakki E. Nonalcoholic steatohepatitis-induced hepatocellular carcinoma. King Khalid Univ J Health Sci 2022;7:1. [DOI: 10.4103/kkujhs.kkujhs_1_22] [Reference Citation Analysis]
30 Kahl S. Die Rolle der nicht-alkoholischen Fettlebererkrankung für den gewebespezifischen Energiestoffwechsel und die Insulinsensitivität vor und nach Adipositaschirurgie – Hans-Christian-Hagedorn-Projektförderung 2021 – eine Kurzübersicht der Geförderten Sabine Kahl. Diabetologie und Stoffwechsel 2021;16:480-1. [DOI: 10.1055/a-1664-5206] [Reference Citation Analysis]
31 Younossi ZM, Henry L. Fatty Liver through the Ages- Non-Alcoholic Steatohepatitis (NASH). Endocr Pract 2021:S1530-891X(21)01417-8. [PMID: 34952219 DOI: 10.1016/j.eprac.2021.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
32 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines 2021;9:1524. [PMID: 34829753 DOI: 10.3390/biomedicines9111524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
33 Polyakova OA, Ostroumova OD, Kovaleva GP, Pavleeva EE. Comorbidity of non-alcoholic fatty liver disease and cardiovascular disease: focus on ademetionine and ursodeoxycholic acid. Medicinskij alfavit 2021;1:13-20. [DOI: 10.33667/2078-5631-2021-29-13-20] [Reference Citation Analysis]
34 Yang C, Wan M, Xu D, Pan D, Xia H, Yang L, Sun G. Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis. Int J Mol Sci 2021;22:10858. [PMID: 34639207 DOI: 10.3390/ijms221910858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Hliwa A, Ramos-Molina B, Laski D, Mika A, Sledzinski T. The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update. Int J Mol Sci 2021;22:6900. [PMID: 34199035 DOI: 10.3390/ijms22136900] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]